Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) fell 2.8% on Thursday . The stock traded as low as $2.25 and last traded at $2.28. 7,557 shares traded hands during trading, a decline of 90% from the average session volume of 78,265 shares. The stock had previously closed at $2.34.
CytoMed Therapeutics Stock Down 2.8%
The company has a current ratio of 9.89, a quick ratio of 9.89 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $2.26 and a 200-day moving average of $2.49.
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Featured Stories
- Five stocks we like better than CytoMed Therapeutics
- How to find penny stocks to invest and trade
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- What is Insider Trading? What You Can Learn from Insider Trading
- Is IBM’s AI Transformation Powering a Sustained Rally?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
